Patients Receiving Eculizumab (Soliris®) at High Risk for Invasive Meningococcal Disease Despite Vaccination [July 7, 2017, 11:00 ET (11:00 AM ET)]

Details

• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.). Health Alert Network (HAN)
• Description:
  July 7, 2017, 11:00 ET (11:00 AM ET)
  
  CDCHAN-00404
  
  Summary: Eculizumab (Soliris®) recipients have a 1,000 to 2,000-fold greater risk of invasive meningococcal disease compared to the general U.S. population. The Food and Drug Administration (FDA)-approved prescribing information for eculizumab includes a black box warning for increased risk of meningococcal disease, and the Advisory Committee on Immunization Practices (ACIP) recommends meningococcal vaccination for all patients receiving eculizumab. Recent data show that some patients receiving eculizumab who were vaccinated with the recommended meningococcal vaccines still developed meningococcal disease, most often from nongroupable Neisseria meningitidis, which rarely causes invasive disease in healthy individuals.
  
  Background: Eculizumab is most commonly prescribed for treatment of 2 rare blood disorders: atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). Through a request for data on meningococcal disease cases reported to state health departments, the U.S. Centers for Disease Control and Prevention (CDC) identified 16 cases of meningococcal disease in eculizumab recipients in the United States from 2008 through 2016; 11 (69%) of these were caused by nongroupable N. meningitidis. Meningococcal conjugate (MenACWY) vaccine targets serogroups A, C, W, and Y, and provides no protection against nongroupable N. meningitidis. Serogroup B meningococcal (MenB) vaccines are licensed specifically for protection against serogroup B meningococcal disease. Researchers have not assessed the extent of any potential cross protection for nongroupable N. meningitidis strains.
  
  Recommendations for Healthcare Providers:
  
  Healthcare Providers:
  
  • Could consider antimicrobial prophylaxis for the duration of eculizumab therapy to potentially reduce the risk of meningococcal disease.
  
  • Should continue meningococcal vaccination of all patients who receive eculizumab.
  
  • Should administer meningococcal vaccines at least 2 weeks prior to administering the first dose of eculizumab, unless the risks of delaying eculizumab therapy outweigh the risks of developing a meningococcal infection, according to the product label.
  
  • Should maintain a high index of suspicion for meningococcal disease in patients taking eculizumab who present with any symptoms consistent with either meningitis or meningococcemia, even if the patient’s symptoms initially appear mild, and irrespective of the patient’s meningococcal vaccine or antimicrobial prophylaxis status.
  
  
• Content Notes:
  Notice of Possible Alert Expiration: The CDC Health Alert, Advisory, Update, and Info Service announcements, distributed by the Health Alert Network (HAN), were active on the date they were originally published. Publication dates have been added to Titles for clarity. A CDC Health Alert, Advisory, Update, and Info Service announcement may expire at any time. They may also be updated or superseded according to later developments. None of the CDC Health Alert, Advisory, Update, or Info Service announcements in the Stacks HAN Collection should be assumed to be current or active. Stacks preserves HAN announcements in order to maintain a record of past CDC actions. Stacks in not designed for up-to-the-minute notifications. For the list of current CDC Health Alert, Advisory, Update, or Info Service announcements, patrons should visit the Health Alert Network (HAN) webpage at https://www.cdc.gov/han/php/about/index.html. For up to the minute reports, subscribe to the HAN email alert system hosted by CDC News & Updates at https://tools.cdc.gov/campaignproxyservice/subscriptions.aspx?topic_id=USCDC_486
  
  Categories of Health Alert Network (HAN) messages:
  
  Health Alert: Requires immediate action or attention, highest level of importance.
  
  Health Advisory: May not require immediate action; provides important information for a specific incident or situation.
  
  Health Update: Unlikely to require immediate action; provides updated information regarding an incident or situation.
  
  HAN Info Service: Does not require immediate action; provides general public health information.
  
  
• Subjects:
  Eculizumab Meningitis, Meningococcal Meningococcal Infections Neisseria Meningitidis
• Keywords:
  HAN Health Alert Network
• Source:
  HAN ; 404
• Series:
  Health Alert Network
• Subseries:
  CDC Health Advisory
• Publisher:
  Centers for Disease Control and Prevention (CDC) (U.S.)
• Document Type:
  Text
• Genre:
  Alert
• Place as Subject:
  Illinois ; Minnesota ; Montana
• Rights:
  Public Domain
• Pages in Document:
  2 unnumbered pages
• Issue:
  00404
• Collection(s):
  Health Alert Network (HAN)
• Main Document Checksum:
  urn:sha-512:23282e0f0ac45e8bd1e34b31bcef0f00033d13c9f7aaf13fd5eff576684a6ae7cf0873d35e1b81825a3c0f569b28533f8df6663c5327b2613d1929ee3ca41a26
• Download URL:
  https://stacks.cdc.gov/view/cdc/46574/cdc_46574_DS1.pdf
• File Type:
  [PDF - 52.97 KB ]